High-quality, purified proteins are pivotal in driving innovation within vaccine development. Whether producing split virus vaccines or working with native pools of antigens, these proteins underpin the structural integrity and efficacy of vaccines. From creating vaccines against influenza, leptospirosis, HIV, and Chikungunya, these stabilized antigens serve as a cornerstone for enhancing immunization strategies and ultimately advancing healthcare.
In the realm of split virus vaccines, the technique of splitting enveloped viruses into native membrane antigens has revolutionized the creation of inactivated viruses, ensuring that the structural integrity of these vital components remains intact. For influenza vaccines, the egg-based production method provides a foundation for vaccine efficacy.
Virus splitting is a key step for the vaccine preparation process that requires detergent use. However, it is challenging to obtain an efficient virus splitting while maintaining immunogenicity using classical detergents. Eurofins CALIXAR's innovative surfactant and detergent-based approach has revolutionized virus splitting and antigen stabilization, ensuring efficient vaccine preparation without compromising immunogenicity. This proprietary method has demonstrated success in low-dose split inactivated vaccine development for influenza and holds promise for other enveloped viruses like Arbovirus (Mandon E et al., Vaccine, 2020) and HIV (Jawhari A et al., World Vaccine Congress, Washington 2017).
The workflow used to generate and analyze fragmentation of purified egg-based NYMC X-179A (A(H1N1)) virus using triton-X100 or CALX-R compound. This includes virus production, virus fragmentation, dialysis/ultrafiltration/formaldehyde inactivation, in vitro hemagglutination (HA) and single radial immunodiffusion assays (SRID), and in vivo validation. Each step is designed to ensure that the final vaccine product is both safe and effective.
The advancements in protein purification and vaccine development underscore the importance of utilizing high-quality proteins. As the demand for effective vaccines continues to rise, especially in the wake of global health crises, the ability to produce and purify recombinant proteins efficiently becomes increasingly vital. By leveraging innovative technologies and methodologies, organizations can enhance their vaccine development processes, ensuring that they are prepared to meet future challenges in public health.
References :
Mandon E et al., Vaccine, 2020
